Stock IKPM PT IKAPHARMINDO PUTRAMAS TBK
Add to a list
To use this feature you must be a member
Log inSign up

Financials PT Ikapharmindo Putramas Tbk

Equities

IKPM

ID1000199409

Pharmaceuticals

End-of-day quote INDONESIA S.E.
Other stock markets
 23:00:00 06/06/2024 BST 		5-day change 1st Jan Change
224 IDR -0.88% Intraday chart for PT Ikapharmindo Putramas Tbk +2.75% +10.89%
05-17 PT Ikapharmindo Putramas Tbk Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-29 PT Ikapharmindo Putramas Tbk Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2023
Capitalization 1 340,302
Enterprise Value (EV) 1 445,409
P/E ratio 11.8 x
Yield -
Capitalization / Revenue 0.77 x
EV / Revenue 1.01 x
EV / EBITDA 10.6 x
EV / FCF -14,778,883 x
FCF Yield -0%
Price to Book 1.39 x
Nbr of stocks (in thousands) 1,684,663
Reference price 2 202.0
Announcement Date 29/04/24
1IDR in Million2IDR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales 1 715,801 380,917 398,735 441,137
EBITDA 1 44,943 36,767 43,116 41,844
EBIT 1 31,666 25,005 33,226 31,780
Operating Margin 4.42% 6.56% 8.33% 7.2%
Earnings before Tax (EBT) 1 10,773 12,111 22,721 20,785
Net income 1 4,628 8,125 16,578 15,338
Net margin 0.65% 2.13% 4.16% 3.48%
EPS 2 4.628 8.125 16.58 17.08
Free Cash Flow - 181,991 -11,731 -30,138
FCF margin - 47.78% -2.94% -6.83%
FCF Conversion (EBITDA) - 494.98% - -
FCF Conversion (Net income) - 2,239.81% - -
Dividend per Share - - - -
Announcement Date 20/10/23 20/10/23 20/10/23 29/04/24
1IDR in Million2IDR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 225,255 124,465 133,351 105,107
Net Cash position 1 - - - -
Leverage (Debt/EBITDA) 5.012 x 3.385 x 3.093 x 2.512 x
Free Cash Flow - 181,991 -11,731 -30,138
ROE (net income / shareholders' equity) - 3.57% 8.9% 7.28%
ROA (Net income/ Total Assets) - 3.25% 5.38% 4.67%
Assets 1 - 250,109 308,384 328,540
Book Value Per Share 2 258.0 196.0 177.0 145.0
Cash Flow per Share 2 20.80 14.30 10.90 26.30
Capex 1 7,415 2,067 2,990 44,093
Capex / Sales 1.04% 0.54% 0.75% 10%
Announcement Date 20/10/23 20/10/23 20/10/23 29/04/24
1IDR in Million2IDR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
PT IKAPHARMINDO PUTRAMAS TBK Stock PT Ikapharmindo Putramas Tbk
+10.89% 23.3M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+45.82% 765B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.16% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.86% 331B
ABBVIE INC. Stock AbbVie Inc.
+9.32% 299B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.91% 248B
ROCHE HOLDING AG Stock Roche Holding AG
-1.51% 219B
NOVARTIS AG Stock Novartis AG
+11.29% 216B
AMGEN INC. Stock Amgen Inc.
+5.90% 164B
PFIZER, INC. Stock Pfizer, Inc.
-0.73% 162B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. IKPM Stock
  4. Financials PT Ikapharmindo Putramas Tbk
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW